Patents Assigned to IRM LLC
  • Publication number: 20140302553
    Abstract: Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analogue, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporated therein and methods for incorporating PCL into such proteins, polypeptides and peptides. Also disclosed herein is the site-specific derivatization of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein. Also disclosed herein is the crosslinking of proteins, polypeptides and peptides having PCL or pyrrolysine incorporated therein.
    Type: Application
    Filed: May 15, 2014
    Publication date: October 9, 2014
    Applicant: IRM LLC
    Inventors: Bernhard GEIERSTANGER, Weijia OU, Susan E. CELLITTI, Tetsuo UNO, Tiffany CROSSGROVE, Hsien-Po CHIU, Jan GRUNEWALD, Xueshi HAO
  • Publication number: 20140274926
    Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: IRM LLC
    Inventors: Arnab Kumar CHATTERJEE, Fang LIANG, Casey Jacob Nelson MATHISON, Pranab Kumar MISHRA, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Liying Jocelyn TAN, Agnes VIDAL
  • Publication number: 20140275013
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, IRM LLC
    Inventors: Arnab Kumar CHATTERJEE, Fang LIANG, Casey Jacob Nelson MATHISON, Pranab Kumar MISHRA, Valentina MOLTENI, Advait Suresh Nagle, Frantisek SUPEK, Liying Jocelyn TAN, Agnes VIDAL, Michael Herman GELB, Frederick Simmons BUCKNER, Hari Babu TATIPAKA, Neil Richard NORCROSS, John Robert GILLESPIE
  • Publication number: 20140271688
    Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Tinya Abrams, Steven Bruce Cohen, Christie P. Fanton, Thomas Huber, Kathy Miller, Siew Ho Schleyer, Kathrin Ulrike Tissot-Daguette, Catrin Finner
  • Publication number: 20140275119
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: NOVARTIS AG, IRM LLC
    Inventors: Fang LIANG, Pranab Kumar MISHRA, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Liying Jocelyn TAN, Agnes VIDAL
  • Publication number: 20140228347
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: April 22, 2014
    Publication date: August 14, 2014
    Applicant: IRM LLC
    Inventors: Valentina MOLTENI, Hank Michael James PETRASSI, Xiaolin LI, Xiaodong LIU, Jon LOREN, Juliet NABAKKA, Bao NGUYEN, Vince YEH
  • Publication number: 20140206682
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of PDGFR (PDGFR?, PDGFR?) kinases or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: August 31, 2012
    Publication date: July 24, 2014
    Applicants: NOVARTIS PHARMACEUTICALS UK LIMITED, IRM LLC
    Inventors: Fang Liang, Michael Gibney, Vince Yeh, Xiaolin Li, Valentina Molteni, Duncan Shaw, Ashley Mitchell Berman, Sarah Lewis, Jon Loren, Vikki Furminger
  • Publication number: 20140155367
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
    Type: Application
    Filed: November 18, 2013
    Publication date: June 5, 2014
    Applicants: Novartis AG, IRM LLC
    Inventors: Arnab Kumar Chatterjee, Advait Suresh Nagle, Prasuna Paraselli, Ravinder Reddy Kondreddi, Seh Yong Leong, Pranab Kumar Mishra, Robert Joseph Moreau, Jason Thomas Roland, Wei Lin Sandra Sim, Oliver Simon, Liying Jocelyn Tan, Bryan KS Yeung, Bin Zou, Venkatataiah Bollu
  • Patent number: 8722691
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: May 13, 2014
    Assignee: IRM LLC
    Inventors: Xiaohui He, Kunyong Yang, Hong Liu, David Archer Ellis
  • Patent number: 8710192
    Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: April 29, 2014
    Assignees: IRM LLC, Novartis AG
    Inventors: Sarah Rue, Steve B. Cohen, Jun Li, David Yowe
  • Publication number: 20140114070
    Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 24, 2014
    Applicants: THE SCRIPPS RESEARCH INSTITUTE, IRM LLC
    Inventors: ANTHONY E. BOITANO, MICHAEL COOKE, SHIFENG PAN, PETER G. SCHULTZ, JOHN TELLEW, YONGQIN WAN, XING WANG
  • Patent number: 8703787
    Abstract: The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK+ mediated condition such as EML4-ALK+ non-small cell lung cancer, and optionally resistant to crizotinib; wherein R1, R2, R3, R4, R5 and R6 are as defined above.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: April 22, 2014
    Assignee: IRM LLC
    Inventors: Nanxin Li, Jennifer Leslie Harris, Peter McNamara, Fangxian Sun
  • Publication number: 20140038949
    Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.
    Type: Application
    Filed: February 17, 2012
    Publication date: February 6, 2014
    Applicants: IRM LLC, The Scripps Research Institute
    Inventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
  • Patent number: 8642035
    Abstract: The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: February 4, 2014
    Assignee: IRM LLC
    Inventor: Kenneth R. Luehrsen
  • Publication number: 20140031333
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFR?, PDGFR?) kinases.
    Type: Application
    Filed: September 19, 2013
    Publication date: January 30, 2014
    Applicant: IRM LLC
    Inventors: Valentina MOLENTI, Hank Michael James Petrassi, Xiaolin Li, Xiaodong Liu, Jon Loren, Juliet Nabakka, Bao Nguyen, Vince Yeh
  • Patent number: 8637516
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: January 28, 2014
    Assignee: IRM LLC
    Inventors: Yi Fan, Jon Loren, Valentina Molteni, Pamela A. Albaugh, Gregory Chopiuk, Jeffrey M. Smith, Brenton T. Flatt
  • Publication number: 20140011825
    Abstract: The present invention provides compounds of Formula I or II: wherein R1, R1b, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.
    Type: Application
    Filed: September 10, 2013
    Publication date: January 9, 2014
    Applicants: NOVARTIS AG, IRM LLC
    Inventors: Abran Q. Costales, Shenlin Huang, Jeff Xianming Jin, Zuosheng Liu, Sabina Pecchi, Daniel Poon, John Tellew
  • Publication number: 20130345220
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of liver X receptors (LXRs).
    Type: Application
    Filed: August 29, 2013
    Publication date: December 26, 2013
    Applicant: IRM LLC
    Inventors: Valentina MOLTENI, Xiaolin Li, Juliet Nabakka, David Archer Ellis, Beth Anaclerio, Enrique Saez, John Wityak
  • Publication number: 20130338152
    Abstract: The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 8, 2012
    Publication date: December 19, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Stefan Stutz
  • Publication number: 20130331397
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.
    Type: Application
    Filed: February 23, 2012
    Publication date: December 12, 2013
    Applicant: IRM LLC
    Inventors: Valentina Molteni, Yi Fan, Jon Loren, Jeffrey M. Smith, Brenton T. Flatt